Merck & Co., Inc., known as MSD Animal Health outside the United States and Canada, has announced that its new product, BRAVECTO® QUANTUM, has received approval from the U.S. Food and Drug Administration (FDA). This once-yearly injectable treatment provides dogs with year-round protection against fleas and ticks. The product is expected to be available in veterinary clinics and hospitals across the United States by August 2025. BRAVECTO QUANTUM, which utilizes a unique composition of fluralaner, has already been approved in more than 50 countries, including Australia, New Zealand, and the European Union. The product has been recognized with awards for its innovative approach to pet care.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。